191 related articles for article (PubMed ID: 11714800)
1. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
Liu K; Rosenberg SA
J Immunol; 2001 Dec; 167(11):6356-65. PubMed ID: 11714800
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
Liu K; Rosenberg SA
J Immunother; 2003; 26(3):190-201. PubMed ID: 12806273
[TBL] [Abstract][Full Text] [Related]
3. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
5. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
6. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
7. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585
[TBL] [Abstract][Full Text] [Related]
9. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism.
Xu S; Koski GK; Faries M; Bedrosian I; Mick R; Maeurer M; Cheever MA; Cohen PA; Czerniecki BJ
J Immunol; 2003 Sep; 171(5):2251-61. PubMed ID: 12928369
[TBL] [Abstract][Full Text] [Related]
10. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
11. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
Dudley ME; Wunderlich J; Nishimura MI; Yu D; Yang JC; Topalian SL; Schwartzentruber DJ; Hwu P; Marincola FM; Sherry R; Leitman SF; Rosenberg SA
J Immunother; 2001; 24(4):363-73. PubMed ID: 11565838
[TBL] [Abstract][Full Text] [Related]
13. Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
Yamaue H; Kashmiri SV; De Filippi R; Nieroda C; Yannelli JR; Tsang KY; Schlom J
J Immunother Emphasis Tumor Immunol; 1994 Nov; 16(4):262-74. PubMed ID: 7881635
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
[TBL] [Abstract][Full Text] [Related]
15. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
16. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Wang A; Chandran S; Shah SA; Chiu Y; Paria BC; Aghamolla T; Alvarez-Downing MM; Lee CC; Singh S; Li T; Dudley ME; Restifo NP; Rosenberg SA; Kammula US
Sci Transl Med; 2012 Aug; 4(149):149ra120. PubMed ID: 22932225
[TBL] [Abstract][Full Text] [Related]
17. CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
Willemsen RA; Sebestyén Z; Ronteltap C; Berrevoets C; Drexhage J; Debets R
J Immunol; 2006 Jul; 177(2):991-8. PubMed ID: 16818755
[TBL] [Abstract][Full Text] [Related]
18. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
20. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
Rivoltini L; Castelli C; Carrabba M; Mazzaferro V; Pilla L; Huber V; Coppa J; Gallino G; Scheibenbogen C; Squarcina P; Cova A; Camerini R; Lewis JJ; Srivastava PK; Parmiani G
J Immunol; 2003 Oct; 171(7):3467-74. PubMed ID: 14500642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
